...
首页> 外文期刊>Vaccine >Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease
【24h】

Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease

机译:第4章:非癌HPV相关疾病的负担和处理:HPV-6 / 11疾病

获取原文
获取原文并翻译 | 示例

摘要

Human Papillomavirus (HPV)-6 and -11 are the causative agents of ano-genital warts (GWs) and recurrent respiratory papillomatosis (RRP). They are low-risk HPV types that are uncommonly found in malignant lesions. GWs are an extremely prevalent sexually transmitted disease, whereas RRP is a rare disease that can be life threatening and requires multiple surgical procedures. GWs and RRP cause substantial healthcare costs. A quadrivalent HPV-6/11/16/18 vaccine (Merck/SPMSD) has shown essentially 100% protection against GWs in women in early studies. Cost-effectiveness analyses are needed to assess the benefits of the HPV-6/11 virus-like particle (VLP) components of the quadrivalent vaccine in population-based vaccination programmes.
机译:人乳头瘤病毒(HPV)-6和-11是负生殖器疣(GWs)和反复呼吸道乳头状瘤病(RRP)的病原体。它们是低危型HPV,在恶性病变中很少见。 GWs是一种非常普遍的性传播疾病,而RRP是一种罕见的疾病,可能危及生命,需要进行多次外科手术。 GW和RRP导致大量医疗费用。在早期研究中,四价的HPV-6 / 11/16/18疫苗(Merck / SPMSD)已显示出针对女性的GWs基本上具有100%的保护作用。需要进行成本效益分析,以评估基于人群的疫苗接种计划中四价疫苗的HPV-6 / 11病毒样颗粒(VLP)成分的益处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号